IASLC > International Association for the Study of Lung Cancer > Conferences & Events > Event Details
Evolution of Small Cell Lung Cancer Therapy: Chemotherapy and Beyond
December 06, 2017 | Online

Overview

This program will provide an update of current standards of therapy for first- and second line treatment of extensive-stage small cell lung cancer (SCLC). Management of limited-stage disease will also be discussed.  Indications for radiotherapy in the management of limited and extensive stage patients will be addressed. In addition, new directions in SCLC treatment, including immunotherapy and emerging targeted therapy approaches will be presented.  Discussion will also focus on potential biomarkers to direct therapy in SCLC.

What you should expect to learn

After viewing this webinar, attendees will:

  • Recognize current treatment standards for limited and extensive stage SCLC;
  • Identify new immunotherapy and targeted-therapy approaches; and
  • Indicate ongoing and planned clinical trials that will impact patient care in the near future.

Suresh S. Ramalingam, MD

Professor of Hematology and Medical Oncology
Emory University School of Medicine
Winship Cancer Institute

&

Charles Rudin, MD, PhD

Chief, Thoracic Oncology Service
Sylvia Hassenfeld Chair in Lung Cancer Research
Co-Director, Drukenmiller Center 
for Lung Cancer Research
Professor of Medicine, WCMC, Memorial Sloan Kettering Cancer Center

Contact